Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study.
Am J Hematol
; 98(11): 1742-1750, 2023 Nov.
Article
in En
| MEDLINE
| ID: mdl-37647123
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
Language:
En
Journal:
Am J Hematol
Year:
2023
Document type:
Article
Affiliation country:
China
Country of publication:
Estados Unidos